Form 4: Coya Therapeutics CMO Granted Stock Options

Coya Therapeutics' Chief Medical Officer, Fred Grossman, was granted 140,041 stock options with an exercise price of $4.73, vesting over 36 months.

Summary

• Fred Grossman, Chief Medical Officer of Coya Therapeutics, Inc. (COYA), was granted 140,041 stock options.
• The options have an exercise price of $4.73 per share.
• The grant date for these options was January 22, 2026.
• The options expire on January 22, 2036.
• Vesting occurs in monthly installments over 36 months, subject to continuous service.
• Full vesting and immediate exercisability will occur upon a change in control of the Issuer, as per the 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a neutral to slightly positive event, indicating standard compensation practices and an effort to align management incentives with shareholder interests. It is not a major market moving event on its own.

Positives

• Aligns management's interests with shareholders through equity ownership.
• Incentivizes long-term performance and retention of a key executive.
• The vesting schedule encourages continuous service over 36 months.

Negatives

• Potential for future dilution if all options are exercised.
• The exercise price of $4.73 is the current market price at grant, so there is no immediate 'in-the-money' value.

Risks

• Future stock price performance is uncertain, meaning the options may not become valuable.
• Risk of dilution for existing shareholders if options are exercised.

Future Outlook

The vesting schedule and change-of-control clause indicate a strategic approach to executive retention and alignment with long-term company performance, particularly in the context of potential future corporate events.

Industry Context

Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to incentivize leadership and align their financial interests with the company's long-term success and shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of executive interests with shareholder value creation.
• Employees: Standard executive compensation practices can positively influence morale and retention of other key personnel.

Next Steps

• Continued service by Fred Grossman to fulfill vesting conditions.
• Potential future exercise of options if the stock price appreciates above $4.73.

Key Dates

Keywords

Coya Therapeutics, COYA, Fred Grossman, Stock Options, Form 4, Insider Transaction, Equity Incentive Plan, Chief Medical Officer, Executive Compensation